Showing results (41-50 of 56) with videos related to
Sort By:
Pageof 6
Blood Advances|May 13, 2024
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16Peter Mollee, John Reynolds, Wojt Janowski, et al.Leukemia & Lymphoma|July 15, 2021
Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD)Anna Kalff, Tiffany Khong, Malarmathy Ramachandran, et al.Science (New York, N.Y.)|November 6, 2025
The need for a global effort to attend to human neural organoid and assembloid researchSergiu P Pașca, Paola Arlotta, Philip Campbell, et al.JAMA Neurology|January 14, 2020
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled TrialStephen Mullin, Laura Smith, Katherine Lee, et al.Research and Practice in Thrombosis and Haemostasis|August 21, 2023
Direct oral anticoagulants or vitamin K antagonists in emergencies: comparison of management in an observational studyRoss I Baker, Grace Gilmore, Vivien Chen, et al.Journal of Synchrotron Radiation|November 5, 2021
NanoMAX: the hard X-ray nanoprobe beamline at the MAX IV LaboratoryUlf Johansson, Dina Carbone, Sebastian Kalbfleisch, et al.Journal of Synchrotron Radiation|May 5, 2022
Design and performance of a dedicated coherent X-ray scanning diffraction instrument at beamline NanoMAX of MAX IVDina Carbone, Sebastian Kalbfleisch, Ulf Johansson, et al.The Lancet. Oncology|November 25, 2015
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trialFrancesca Gay, Stefania Oliva, Maria Teresa Petrucci, et al.European Journal of Heart Failure|October 25, 2024
Effect of correcting iron deficiency on the risk of serious infection in heart failure: Insights from the IRONMAN trialPaul W Foley, Paul R Kalra, John G F Cleland, et al.The Lancet. Oncology|April 12, 2025
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trialMaria-Victoria Mateos, Jesus San-Miguel, Michele Cavo, et al.Pageof 6